The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer:an analysis based on updated results from the HERA Trial

Skedgel, Chris ORCID: https://orcid.org/0000-0003-4989-8846, Rayson, Daniel and Younis, Tallal (2009) The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer:an analysis based on updated results from the HERA Trial. Value in Health, 12 (5). pp. 641-648. ISSN 1524-4733

Full text not available from this repository. (Request a copy)

Abstract

The efficacy of sequential adjuvant trastuzumab (aTZ) after chemotherapy in women with early-stage human epidermal growth factor-2 (HER2/neu)-positive breast cancer reported by the updated Herceptin Adjuvant (HERA) trial appears less favorable than originally reported. Based on these updated results, we estimated the cost-utility (CU) of sequential aTZ relative to chemotherapy alone in terms of incremental cost per quality-adjusted life-year (QALY) gained.

Item Type:	Article
Uncontrolled Keywords:	breast cancer,cost-utility,net-benefits,relative risk,trastuzumab,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	Pure Connector
Date Deposited:	04 Feb 2015 12:20
Last Modified:	20 Oct 2022 22:33
URI:	https://ueaeprints.uea.ac.uk/id/eprint/51931
DOI:	10.1111/j.1524-4733.2009.00511.x

Actions (login required)

View Item